Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets

This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.

Participants needed: 112
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: InnovStone Therapeutics LimitedUpdated: Jun 15, 2026Locations: 1
Eligibility criteria

Participants must be fully informed about the study content, procedures, and pot... [+4]

History of severe allergic diseases or allergic constitution (allergy to ≥ 3 dru... [+21]

Read more
Status: Not yet recruiting

A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe the PK profile of SYH2059 tablets in adult IPF patients, and assess the population pharmacokinetic (PPK) profile, exposure-response (E-R) relationship, as well as the changing trends of blood biomarkers.

Participants needed: 156
Trial details
Phase: Phase 2Age: 40+Biological sex: AllType: InterventionalSponsor: InnovStone Therapeutics LimitedUpdated: May 20, 2026
Eligibility criteria

1. Age ≥ 40 years, regardless of gender; [+5]

1. Interstitial lung disease other than IPF. [+23]

Read more
Status: Not yet recruiting

A Single- and Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2059 Powder for Inhalation

Randomized, double-blind and placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of SYH2059 powder for inhalation after single and multiple doses in healthy subjects. The study is composed of 2 parts. Part 1 is to assess the safety, tolerability and pharmacokinetics of a single ascending dose of SYH2059 powder for inhalation. Part 2 is to assess the safety, tolerability and pharmacokinetics of a multiple ascending dose of SYH2059 powder for inhalation.

Participants needed: 84
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: InnovStone Therapeutics LimitedUpdated: Apr 6, 2026
Eligibility criteria

1) Adults aged 18 ~ 55 years (inclusive), male or female; [+3]

1) History of neurological/psychiatric system, respiratory, endocrine, hematolog... [+27]

Read more